Assistant Professor of Internal Medicine
Faculty of Medicine, School of Health Sciences, University of Ioannina
1st Department of Internal Medicine, University General Hospital of Ioannina
Research Projects
EPIRUS FH Reverse Cascade Screening
ClinicalTrials.gov Identifier: NCT05825612
The EPIRUS-FH registry is a model reverse screening program for familial hypercholesterolemia (FH) in children and adolescents in Northwest Greece that aims to increase public and physician awareness, to strengthen the national registry of familial hypercholesterolemia (HELLAS-FH) and to form the core for a national registry of children and adolescents with FH in Greece..
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial
ClinicalTrials.gov Identifier: NCT05581303
This study will investigate the effect of olpasiran, a drug that lowers Lp(a)-lipoprotein(a) levels, in reducing morbidity and mortality in adults with coronary artery disease
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation (ZEUS)
ClinicalTrials.gov Identifier: NCT05021835
This study is being conducted to see if ziltivekimab reduces the risk of cardiovascular events (for example heart attack and stroke) in people with cardiovascular disease, chronic kidney disease and inflammation.
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity (SURMOUNT-MMO)
ClinicalTrials.gov Identifier: N CT05556512
This study will investigate the effect of tirzepatide on reducing morbidity and mortality in adults living with obesity and provide additional evidence for the potential clinical benefits of tirzepatide in this population.
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease (VICTORION-2P)
ClinicalTrials.gov Identifier: NCT05030428
This study investigates the effect of inclisiran, a cholesterol-lowering drug, on the risk of cardiovascular events in people with established cardiovascular disease.
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke (VESALIUS-CV)
ClinicalTrials.gov Identifier: NCT03872401
This study will evaluate the effect of evolocumab, a cholesterol-lowering drug, on the risk of major cardiovascular events in adults without a previous myocardial infarction or stroke who are at high risk for a cardiovascular event.
